Global Information
회사소개 | 문의 | 비교리스트

세계의 유모세포 백혈병 시장 : 치료법별, 지역별 - 성장, 동향, 예측(2018-2023년)

Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)

리서치사 Mordor Intelligence LLP
발행일 2020년 02월 상품 코드 660532
페이지 정보 영문
가격
US $ 4,250 ₩ 5,136,000 PDF by E-mail (Single User License)
US $ 4,750 ₩ 5,740,000 PDF by E-mail (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,251,000 PDF by E-mail (Site License)
US $ 7,500 ₩ 9,064,000 PDF by E-mail (Corporate License)


세계의 유모세포 백혈병 시장 : 치료법별, 지역별 - 성장, 동향, 예측(2018-2023년) Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)
발행일 : 2020년 02월 페이지 정보 : 영문

세계의 유모세포 백혈병 시장은 2018-2023년의 예측기간 중 5%의 연평균 성장률(CAGR)로 성장할 전망입니다. 유모세포 백혈병은 비정상 림프구의 축적과 관련된 혈액암의 일종입니다.

세계의 유모세포 백혈병(Hairy Cell Leukaemia) 시장에 대해 조사했으며, 전체적인 시장 동향, 제품·지역별 동향, 시장 성장에 대한 영향요인, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

목차

제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 영향요인

제5장 시장 개요

  • 현재 시장 시나리오
  • Porter's Five Forces 분석
    • 공급업체의 협상력
    • 소비자의 협상력
    • 신규 참여업체의 위협
    • 대체 제품 및 서비스의 위협
    • 업계내에서의 경쟁

제6장 성장 촉진요인, 성장 저해요인, 기회, 과제 분석(DROC)

  • 시장 성장 촉진요인
    • 진단률 상승
    • 고령자 인구 증가
  • 시장 성장 저해요인
    • 중요하지 않은 조사 연구 때문에 증상에 대한 인식이 결여
    • 지방 병원의 한정된 보건 서비스
  • 시장 기회
  • 주요 과제

제7장 시장 세분화

  • 치료법별
    • 화학요법
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제8장 경쟁 상황

  • M&A 분석
  • 합의, 협업, 파트너십
  • 신제품 발매

제9장 주요 기업

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Biogenomics Limited
  • F. Hoffmann-La Roche AG
  • Incyte Corp.
  • Juno Therapeutics
  • MedImmune
  • Novartis
  • 기타

제10장 시장의 향후 전망

KSM 18.07.19

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Hairy cell leukemia is a very rare type of cancer, which accounts for approximately 2%, out of all the leukemia's. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow. According to National Organization for Rare Disorders, approximately 600-800 new cases are diagnosed each year in the United States. Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect the hairy cell leukemia. First and foremost diagnostic test is a complete blood profile which clearly indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose, if there is an enlarged spleen, by physical examination. One important confirmation test is presence of hairy cells in the blood in the lab tests. Most of the patients also require bone marrow biopsy for confirmation. Diagnosis rate of hairy cell leukaemia is increased during last two-three decades, which is expected to drives the market in the forecast period.

Key Market Trends

Chemotherapy Segment is Expected to Register a Significant Growth Over the Forecast Period

Based on therapy, it is segmented into chemotherapy and Targeted Therapy. The key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society estimates, there were around 22,840 death from leukemia in 2019. Many companies are focusing on developing breakthrough products for the treatment of hairy cell leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia. Additionally, the increase in funding for companies involved in the research related to hairy cell leukemia is expected to boost the studied market.

North America holds the Largest Share in the Hairy Cell Leukemia Market

The hairy cell leukemia market holds the largest share in North America region due to the presence of high incidence rate, increase in geriatric population and advancements in the treatment of hairy cell leukaemia. According to National Organization for Rare Disorders, Hairy cell leukemia is a rare type of blood cancer, that affects about 6,000 persons in the United States. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool and emerging economies in these regions.

Competitive Landscape

The hairy cell leukemia market is competitive and many of the global players are into the market. For instance - Amgen Inc, AstraZeneca plc, BioGenomics Limited, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Merck KGaA, Merck & Co, Inc. and Pfizer Inc. are providing these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Leukemia Cases
    • 4.2.2 Increase in Diagnosis Rates
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness
    • 4.3.2 Limited Health Services in Rural Hospitals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Targeted Therapy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca plc
    • 6.1.3 BioGenomics Limited
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Incyte Corp
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Merck KGaA
    • 6.1.8 Merck & Co, Inc.
    • 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q